The vaccine candidate is undergoing safety and efficacy studies in animals, according to the firm, which expects to have preclinical data by early July. Once preclinical trials are complete, CDX-005 will be tested in a phase I trial in the fall, according to the firm.

CDX-005 is one of the few vaccine candidates currently under development using the live-attenuated approach, which mimics SARS-CoV-2.

The company is collaborating with the Serum Institute of India to develop CDX-005 which will conduct the phase I clinical trial in the fall. The compound grows rapidly in cell culture, which means that it can be produced quickly, Codagenix said.

Saiba selects AGC to manufacture COVID-19 vaccine
Contract development and manufacturing organization AGC Biologics said it will be manufacturing a SARS-CoV-2 vaccine for Swiss biotechnology firm Saiba.

Moderna moves COVID-19 vaccine to late-stage clinical trial
Moderna has finalized phase III clinical study protocols for its mRNA-1273 COVID-19 vaccine candidate in coordination with the U.S. Food and Drug Administration...

J&J to start clinical trial for COVID-19 vaccine in July
Johnson & Johnson is accelerating its investigational SARS-CoV-2 vaccine candidate, Ad26.COV2-S, recombinant, with the initiation of a phase I/IIA...

Panacea, Refana collaborate on COVID-19 vaccine
Panacea Biotec and Refana are partnering on an inactivated virus-based vaccine for COVID-19 through a joint venture company that will be based in Ireland.

COVID-19 vaccine candidates show progress amid challenges
As the COVID-19 outbreak advances worldwide, companies are stepping up to the challenge to develop a potential vaccine. There are over 75 confirmed COVID-19...